FDAapproval84% confidence
FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to TRAVERE; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
By clarifying FDA’s regulatory expectations for new entrants and experienced drug developers alike, FDA is supporting prospective generic drug developers and improving the overall quality of ANDAs submitted to the Agency for approval.
Supporting Context
- Therapeutic area
- Nephrology · SGLT2 Inhibitor
- Sub-indication
- General
Related signal: FDA Accepts Supplement for FILSPARI (SPARSENTAN) by TRAVERE
Source
FDA document
View source